Heron Therapeutics Inc (NASDAQ:HRTX) has a beta value of 1.68 and has seen 3.93 million shares traded in the last trading session. The company, currently valued at $460.01M, closed the last trade at $3.06 per share which meant it gained $0.01 on the day or 0.33% during that session. The HRTX stock price is -5.23% off its 52-week high price of $3.22 and 83.66% above the 52-week low of $0.50. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.06 million shares traded. The 3-month trading volume is 3.12 million shares.
Heron Therapeutics Inc (NASDAQ:HRTX) trade information
Sporting 0.33% in the green in last session, the stock has traded in the green over the last five days, when the HRTX stock price touched $3.06 or saw a rise of 4.97%. Year-to-date, Heron Therapeutics Inc shares have moved 80.00%, while the 5-day performance has seen it change 17.69%. Over the past 30 days, the shares of Heron Therapeutics Inc (NASDAQ:HRTX) have changed 12.50%. Short interest in the company has seen 24.53 million shares shorted with days to cover at 12.11.
Heron Therapeutics Inc (HRTX) estimates and forecasts
Figures show that Heron Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 139.06% over the past 6 months, with this year growth rate of 72.50%, compared to 11.30% for the industry. Other than that, the company has, however, increased its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are 66.70% and 80.00% for the next quarter. Revenue growth from the last financial year stood is estimated to be 14.90%.
3 analysts offering their estimates for the company have set an average revenue estimate of $32.8 million for the current quarter. 3 have an estimated revenue figure of $34.37 million for the next quarter concluding in Jun 2024. Year-ago sales stood $29.61 million and $31.76 million respectively for this quarter and the next, and analysts expect sales will grow by 10.80% for the current quarter and 8.20% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 20.01% over the past 5 years. Earnings growth for 2024 is a modest 73.33% while over the next 5 years, the company’s earnings are expected to increase by 47.50%.
HRTX Dividends
Heron Therapeutics Inc is expected to release its next earnings report on March 12 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Heron Therapeutics Inc (NASDAQ:HRTX)’s Major holders
Insiders own 0.89% of the company shares, while shares held by institutions stand at 76.09% with a share float percentage of 76.78%. Investors are also buoyed by the number of investors in a company, with Heron Therapeutics Inc having a total of 189 institutions that hold shares in the company. The top two institutional holders are Rubric Capital Management LP with over 11.75 million shares worth more than $13.63 million. As of Jun 29, 2023, Rubric Capital Management LP held 8.35% of shares outstanding.
The other major institutional holder is Blackrock Inc., with the holding of over 8.38 million shares as of Jun 29, 2023. The firm’s total holdings are worth over $9.72 million and represent 5.95% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are JP Morgan Small Cap Growth Fund and Vanguard Total Stock Market Index Fund. As of Jun 29, 2023, the former fund manager holds about 2.81% shares in the company for having 3.95 million shares of worth $4.58 million while later fund manager owns 3.61 million shares of worth $4.18 million as of Jun 29, 2023, which makes it owner of about 2.56% of company’s outstanding stock.
